|
1
|
Zhu Z, Liu W, Gillin M, Gomez DR, Komaki
R, Cox JD, Mohan R and Chang JY: Assessing the robustness of
passive scattering proton therapy with regard to local recurrence
in stage III non-small cell lung cancer: A secondary analysis of a
phase II trial. Radiat Oncol. 9:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahn MJ, Kim SW, Cho BC, Ahn JS, Lee DH,
Sun JM, Massey D, Kim M, Shi Y and Park K: Phase II study of
Afatinib as third-line treatment for patients in Korea with stage
IIIB/IV non-small cell lung cancer harboring wild-type EGFR.
Oncologist. 19:702–703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou ZY, Xu L, Li HG, Tian JH, Jiao LJ,
You SF, Han ZF, Jiang Y, Guo HR and Liu H: Chemotherapy in
conjunction with traditional Chinese medicine for survival of
elderly patients with advanced non-small-cell lung cancer: Protocol
for a randomized double-blind controlled trial. J Integr Med.
12:175–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamasaki M, Murakami I, Nakano K, Doi M,
Kitaguchi S, Kondo T, Sakurai J, Hattori N and Arita KI:
Carboplatin plus Weekly paclitaxel combined with bevacizumab as
first-line treatment for non-small cell lung cancer. Anticancer
Res. 37:923–928. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hida T, Nakagawa K, Seto T, Satouchi M,
Nishio M, Hotta K, Takahashi T, Ohe Y, Takeda K, Tatsuno M, et al:
Pharmacologic study (JP28927) of alectinib in Japanese patients
with ALK+ non-small-cell lung cancer with or without
prior crizotinib therapy. Cancer Sci. 107:1642–1646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Voortman J, Goto A, Mendiboure J, Sohn JJ,
Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, et al:
MicroRNA expression and clinical outcomes in patients treated with
adjuvant chemotherapy after complete resection of non-small cell
lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhan X, Wu W, Han B, Gao G, Qiao R, Lv J,
Zhang S, Zhang W, Fan W, Chen H, et al: Hsa-miR-196a2 functional
SNP is associated with severe toxicity after platinum-based
chemotherapy of advanced nonsmall cell lung cancer patients in a
Chinese population. J Clin Lab Anal. 26:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neal JW, Dahlberg SE, Wakelee HA, Aisner
SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin
JL, et al: Erlotinib, cabozantinib, or erlotinib plus cabozantinib
as second-line or third-line treatment of patients with EGFR
wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): A
randomised, controlled, open-label, multicentre, phase 2 trial.
Lancet Oncol. 17:1661–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Planken S, Behenna DC, Nair SK, Johnson
TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H,
et al: Discovery of
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide
(PF-06747775) through structure-based drug design: A high affinity
irreversible inhibitor targeting oncogenic EGFR mutants with
selectivity over wild-type EGFR. J Med Chem. 60:3002–3019. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Q, Zhu H, Xu X, Li L, Tan H and Cai
X: Inactivated Sendai virus induces apoptosis and autophagy via the
PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer
cells. Biochem Biophys Res Commun. 465:64–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin CH, Lin HH, Kuo CY and Kao SH:
Aeroallergen Der p 2 promotes motility of human non-small cell lung
cancer cells via toll-like receptor-mediated up-regulation of
urokinase-type plasminogen activator and integrin/focal adhesion
kinase signaling. Oncotarget. 8:11316–11328. 2017.PubMed/NCBI
|
|
13
|
Qiao L, Wang J, Long G and Jiang Y:
Sequential treatment of tyrosine kinase inhibitor and
platinum-based doublet chemotherapy on EGFR mutant non-small cell
lung cancer: A meta-analysis of randomized controlled clinical
trials. Onco Targets Ther. 10:1279–1284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uchibori K, Inase N, Araki M, Kamada M,
Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with
anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated
non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo Y, Sun W, Gong T, Chai Y, Wang J, Hui
B, Li Y, Song L and Gao Y: miR-30a radiosensitizes non-small cell
lung cancer by targeting ATF1 that is involved in the
phosphorylation of ATM. Oncol Rep. 37:1980–1988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang C, Chen YX, Wu NY, Yin JY, Li XP,
Huang HS, Zhang W, Zhou HH and Liu ZQ: MiR-488 inhibits
proliferation and cisplatin sensibility in non-small-cell lung
cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling
pathway. Sci Rep. 7:403842017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu X, Long L, Liu J, Zhang J, Wu T, Chen
X, Zhou B and Lv TZ: Gambogic acid suppresses inflammation in
rheumatoid arthritis rats via PI3K/Akt/mTOR signaling pathway. Mol
Med Rep. 16:7112–7118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mulvenna P, Nankivell M, Barton R,
Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D,
Holt T, et al: Dexamethasone and supportive care with or without
whole brain radiotherapy in treating patients with non-small cell
lung cancer with brain metastases unsuitable for resection or
stereotactic radiotherapy (QUARTZ): Results from a phase 3,
non-inferiority, randomised trial. Lancet. 388:2004–2014. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu J, Wang S, Zhang W, Qiu J, Shan Y,
Yang D and Shen B: Screening key microRNAs for castration-resistant
prostate cancer based on miRNA/mRNA functional synergistic network.
Oncotarget. 6:43819–43830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marquez-Medina D and Popat S: Eventual
role of EGFR-tyrosine kinase inhibitors in early-stage
non-small-cell lung cancer. Future Oncol. 12:815–825. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, Jiang X, Song Z and Zhang Y:
Patients harboring EGFR mutation after primary resistance to
crizotinib and response to EGFR-tyrosine kinase inhibitor. Onco
Targets Ther. 9:211–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nand M, Maiti P, Pant R, Kumari M, Chandra
S and Pande V: Virtual screening of natural compounds as inhibitors
of EGFR 696–1022 T790M associated with non-small cell lung cancer.
Bioinformation. 12:311–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sheng Z and Zhang Y: EGFR-TKIs combined
with chemotherapy versus EGFR-TKIs single agent as first-line
treatment for molecularly selected patients with non-small cell
lung cancer. Med Oncol. 32:4202015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng Z, Dai LL, Wang X, Jia LQ, Jing XG,
Li PF, Liu M, Wang H and An L: MicroRNA-145 down-regulates mucin
5AC to alleviate airway remodeling and targets EGFR to inhibit
cytokine expression. Oncotarget. 8:46312–46325. 2017.PubMed/NCBI
|
|
25
|
Kim N, Jeong S, Jing K, Shin S, Kim S, Heo
JY, Kweon GR, Park SK, Wu T, Park JI, et al: Docosahexaenoic acid
induces cell death in human non-small cell lung cancer cells by
repressing mTOR via AMPK activation and PI3K/Akt inhibition. Biomed
Res Int. 2015:2397642015.PubMed/NCBI
|
|
26
|
Zhang Q, Yan W, Bai Y, Xu H, Fu C, Zheng
W, Zhu Y and Ma J: Synthetic miR-145 mimic inhibits multiple
myeloma cell growth in vitro and in vivo. Oncol Rep.
33:448–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vansteenkiste JF, Canon JL, De Braud F,
Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli
C, et al: Safety and efficacy of Buparlisib (BKM120) in patients
with PI3K pathway-activated non-small cell lung cancer: Results
from the phase II BASALT-1 study. J Thorac Oncol. 10:1319–1327.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Shen Z, Li Z, Duan J, Fu S, Liu Z,
Bai H, Zhang Z, Zhao J, Wang X, et al: Activation of the BMP-BMPR
pathway conferred resistance to EGFR-TKIs in lung squamous cell
carcinoma patients with EGFR mutations. Proc Natl Acad Sci USA.
112:9990–9995. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang XY, Kuang JL, Yan CS, Tu XY, Zhao
JH, Cheng XS and Ye XQ: NRSN2 promotes non-small cell lung cancer
cell growth through PI3K/Akt/mTOR pathway. Int J Clin Exp Pathol.
8:2574–2581. 2015.PubMed/NCBI
|
|
30
|
Boufraqech M, Zhang L, Jain M, Patel D,
Ellis R, Xiong Y, He M, Nilubol N, Merino MJ and Kebebew E: miR-145
suppresses thyroid cancer growth and metastasis and targets AKT3.
Endocr Relat Cancer. 21:517–531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pérez-Ramirez C, Cañadas-Garre M, Molina
MA, Faus-Dáder MJ and Calleja-Hernández MA: PTEN and PI3K/AKT in
non-small-cell lung cancer. Pharmacogenomics. 16:1843–1862. 2015.
View Article : Google Scholar : PubMed/NCBI
|
